TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32660470

Group type: EXPERIMENTAL
Intervention: Bronchodilator response (BDR) in FEV1
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Limit of 400 mL in BDR in FEV1
Number of subjects: 1030
Study: 32660613

Group type: EXPERIMENTAL
Intervention: Metformin treatment for one year
Number of subjects: 88
Study: 32660619

Group type: EXPERIMENTAL
Intervention: NAVIO robot-assisted UKA
Number of subjects: 33

Group type: COMPARATOR
Intervention: MAKO robot-assisted UKA
Number of subjects: 33
Study: 32660634

Group type: EXPERIMENTAL
Intervention: 70° arthroscope
Number of subjects: 47

Group type: COMPARATOR
Intervention: 30° arthroscope
Number of subjects: 47
Study: 32660952

Group type: EXPERIMENTAL
Intervention: Suicide attempt surveillance program with in-depth psychiatric evaluations for suspected suicide risk.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for identifying individual and population-level risk factors.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning techniques for developing risk prediction tools.
Number of subjects: 0
Study: 32661003

Group type: EXPERIMENTAL
Intervention: 400 mg raltegravir twice daily
Number of subjects: 43
Study: 32661186

Group type: EXPERIMENTAL
Intervention: Buparlisib in combination with temozolomide (stage I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buparlisib in combination with temozolomide and radiotherapy (stage II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buparlisib in combination with temozolomide and radiotherapy
Number of subjects: 0
Study: 32661295

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (HSCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32661447

Group type: EXPERIMENTAL
Intervention: Amplification of Positivity (AMP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 29
Study: 32661752

Group type: EXPERIMENTAL
Intervention: 670 nm photobiomodulation (PBM) delivered via a retinal laser, 12 sessions over 5 weeks, 90 seconds per treatment at settings of 25, 100 or 200 mW/cm²
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 670 nm photobiomodulation (PBM) delivered via a light-emitting diode (LED) device
Number of subjects: 21
Study: 32661789

Group type: EXPERIMENTAL
Intervention: Habitual physical activity (HPA)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Higher intensity physical activity
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Poor sleep quality and sleep disturbances
Number of subjects: 109
Study: 32662547

Group type: EXPERIMENTAL
Intervention: Actionable pharmacogenomic diplotypes/phenotypes; 12 pharmacogenomic genes with 30 variants were selected.
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Actionable pharmacogenomic diplotypes/phenotypes for medications including tacrolimus, azathioprine, clopidogrel, warfarin, simvastatin, voriconazole, antidepressants, and proton-pump inhibitors.
Number of subjects: 853
Study: 32662758

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) derived from cardiac CT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very low BMD (<80 mg/cm³)
Number of subjects: 0
Study: 32663093

Group type: EXPERIMENTAL
Intervention: Pediatric weight management interventions; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details not available.
Number of subjects: 0
Study: 32663160

Group type: EXPERIMENTAL
Intervention: 16-week wearable robotic exoskeleton-assisted walking program
Number of subjects: 20
Study: 32664015

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 62
Study: 32664022

Group type: EXPERIMENTAL
Intervention: Full PTSD diagnosis with subthreshold empirical categorization
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Subthreshold PTSD diagnosis with full PTSD empirical grouping
Number of subjects: 353

Group type: COMPARATOR
Intervention: Reference group (full PTSD diagnosis and empirical categorization)
Number of subjects: 353
Study: 32664088

Group type: EXPERIMENTAL
Intervention: Plasma cytokines and interleukins collected at admission and 24 hours after, measured using enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Matched controls for comparison
Number of subjects: 600
Study: 32664827

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1512
Study: 32664881

Group type: EXPERIMENTAL
Intervention: Laparoscopic modified complete mesocolic excision (mCME)
Number of subjects: 250
Study: 32664901

Group type: EXPERIMENTAL
Intervention: Long-term opioid therapy (LTOT)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Control group (non-opioid analgesics)
Number of subjects: 554
Study: 32664972

Group type: EXPERIMENTAL
Intervention: Implanted standing neuroprosthesis including composite flat interface nerve electrodes (C-FINEs) around the proximal femoral nerves.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Stimulation through nerve cuff electrodes during rehabilitation with standing and quadriceps exercises.
Number of subjects: 1
Study: 32665297

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab (for patients with high-risk pathology)
Number of subjects: 36
Study: 32665314

Group type: EXPERIMENTAL
Intervention: High-normal eGFR (≥103.9 mL/min/1.73 m²)
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Hyperfiltration group
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Deciles 1, 9, and 10 (eGFR <50.9, 50.9-62.7, and ≥103.9 mL/min/1.73 m²)
Number of subjects: 15773
Study: 32665387

Group type: EXPERIMENTAL
Intervention: Evidence-based interventions at scale
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internal control groups
Number of subjects: 0
Study: 32665393

Group type: EXPERIMENTAL
Intervention: PrEP Optimisation Intervention (PrEP-OI) including a PrEP Coordinator and a web-based panel management tool (PrEP-Rx)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PrEP Optimisation Intervention (PrEP-OI)
Number of subjects: 10
Study: 32665391

Group type: EXPERIMENTAL
Intervention: 2BALANCE protocol (cognitive-motor dual-task protocol)
Number of subjects: 0
Study: 32665855

Group type: EXPERIMENTAL
Intervention: Preoperative fluoropyrimidine with radiotherapy (standard treatment)
Number of subjects: 309
Study: 32665955

Group type: EXPERIMENTAL
Intervention: Inactivated Varicella Zoster Vaccine (ZV); details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified); details on intervention not available
Number of subjects: 0
Study: 32666050

Group type: EXPERIMENTAL
Intervention: Vinblastine and nilotinib combination (vinblastine once weekly, nilotinib orally BID for 12 cycles of 28 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Vinblastine alone
Number of subjects: 35
Study: 32666165

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 0
Study: 32666401

Group type: EXPERIMENTAL
Intervention: Dual isotope (DI) SPECT imaging for healthy liver dosimetry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Qualitative assessment of dosimetry methods
Number of subjects: 0
Study: 32666584

Group type: EXPERIMENTAL
Intervention: Labour induction policy
Number of subjects: 21000
Study: 32666871

Group type: EXPERIMENTAL
Intervention: SELUTION Sustained-Limus-Release Drug-Eluting Balloon
Number of subjects: 0
Study: 32666919

Group type: EXPERIMENTAL
Intervention: Web-Based Intervention for Parents and Youths
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 0
Study: 32667228

Group type: EXPERIMENTAL
Intervention: Elevated adiponectin levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32667265

Group type: EXPERIMENTAL
Intervention: Minimally invasively harvested fascia lata autograft (FLA)
Number of subjects: 22
Study: 32667261

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32667729

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system (RAS) drugs
Number of subjects: 10062

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 10062

Group type: EXPERIMENTAL
Intervention: RAS blocker monotherapy
Number of subjects: 10062

Group type: EXPERIMENTAL
Intervention: Diuretic monotherapy
Number of subjects: 10062

Group type: EXPERIMENTAL
Intervention: RAS blocker/diuretic combo
Number of subjects: 10062
Study: 32667736

Group type: EXPERIMENTAL
Intervention: Cine real-time (CRT) sequences
Number of subjects: 229

Group type: COMPARATOR
Intervention: Segmented cine steady-state free precession sequences
Number of subjects: 229
Study: 32667837

Group type: EXPERIMENTAL
Intervention: Reproductive coercion
Number of subjects: 0
Study: 32667835

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32669090

Group type: EXPERIMENTAL
Intervention: AcrySof IQ® PanOptix IOL (TFNT00)
Number of subjects: 44
Study: 32669223

Group type: EXPERIMENTAL
Intervention: Optimal pharmacological treatment (OPT) including lipid lowering drugs
Number of subjects: 83867

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 83867

Group type: EXPERIMENTAL
Intervention: Overall prescription prevalence of OPT
Number of subjects: 83867

Group type: EXPERIMENTAL
Intervention: Differences in patient and healthcare variables
Number of subjects: 83867

Group type: EXPERIMENTAL
Intervention: Time trends in prescription prevalence of OPT
Number of subjects: 83867
Study: 32669376

Group type: EXPERIMENTAL
Intervention: Encorafenib (450 mg) plus Binimetinib (45 mg)
Number of subjects: 126
Study: 32669548

Group type: EXPERIMENTAL
Intervention: HER2 CAR T cells after lymphodepleting chemotherapy, followed by four more CAR T-cell infusions without lymphodepletion.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: One cycle of lymphodepletion and HER2 CAR T cells.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Additional CAR T-cell infusions with pembrolizumab.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: 20 months off T-cell infusions.
Number of subjects: 1
Study: 32669869

Group type: EXPERIMENTAL
Intervention: Vixotrigine 150 mg orally three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32670040

Group type: EXPERIMENTAL
Intervention: Brain Booster cognitive training program (60 hours)
Number of subjects: 6
Study: 32670103

Group type: EXPERIMENTAL
Intervention: Standardized antidepressant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 32670169

Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Number of subjects: 0
Study: 32670261

Group type: EXPERIMENTAL
Intervention: Mass spectrometry-based method for detecting DSA subclasses
Number of subjects: 69

Group type: COMPARATOR
Intervention: Luminex-based test for DSA detection
Number of subjects: 69
Study: 32670418

Group type: EXPERIMENTAL
Intervention: 15-mg crocin, twice daily, for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 32670424

Group type: EXPERIMENTAL
Intervention: UGN-101 (mitomycin gel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32670599

Group type: EXPERIMENTAL
Intervention: 16-week heavy shoulder strengthening exercise programme (3 times weekly) targeting scapular and rotator cuff muscles
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 16-week heavy shoulder strengthening exercise programme
Number of subjects: 12
Study: 32670600

Group type: EXPERIMENTAL
Intervention: Internal Fixation (IF)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Hip Arthroplasty
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Overall Mortality
Number of subjects: 235
Study: 32670812

Group type: EXPERIMENTAL
Intervention: Ketogenic diet supplemented with 10 g essential amino acids
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-ketogenic diet
Number of subjects: 81
Study: 32671084

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32671100

Group type: EXPERIMENTAL
Intervention: Serum GDF15 levels
Number of subjects: 0
Study: 32671131

Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat (DRV/c) for 5 days on top of interferon alpha 2b inhaling
Number of subjects: 30

Group type: COMPARATOR
Intervention: Interferon alpha 2b inhaling alone (Control)
Number of subjects: 30
Study: 32671831

Group type: EXPERIMENTAL
Intervention: CD20-depleting therapy (e.g., rituximab, oblinutuzumab, ofatumumab, ocrelizumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose interruption of CD20-depleting therapy
Number of subjects: 0
Study: 32671834

Group type: EXPERIMENTAL
Intervention: β-carotene
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: KB001-A (monoclonal antibody)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: KB001-A
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Nitric oxide
Number of subjects: 350
Study: 32672147

Group type: EXPERIMENTAL
Intervention: Maternal bipolar disorder
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Maternal major depression
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Affective modeling in early childhood
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Maternal diagnosis
Number of subjects: 131
Study: 32672790

Group type: EXPERIMENTAL
Intervention: Excess soluble fms-like tyrosine kinase 1 (sFlt-1) levels
Number of subjects: 0
Study: 32673037

Group type: EXPERIMENTAL
Intervention: Transdiagnostic behavior therapy (TBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief behavioral activation (BA)
Number of subjects: 0
Study: 32673071

Group type: EXPERIMENTAL
Intervention: Chemokine Receptor 2-targeted Molecular Imaging
Number of subjects: 0
Study: 32673153

Group type: EXPERIMENTAL
Intervention: Pregnancy after breast cancer
Number of subjects: 1252
Study: 32673170

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 105
Study: 32673265

Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia solution (DNS)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Cardi-Braun blood cardioplegia solution
Number of subjects: 474
Study: 32673270

Group type: EXPERIMENTAL
Intervention: Peer-led physical activity intervention (3-month duration, 6 biweekly video chat sessions, Fitbit Charge 3, weekly feedback)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires and MVPA measured using ActiGraph accelerometer at baseline, 3 months, and 6 months
Number of subjects: 30
Study: 32673269

Group type: COMPARATOR
Intervention: Digital personal health profile only
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Targeted intervention at GP or MHC
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 598
Study: 32673274

Group type: EXPERIMENTAL
Intervention: Culturally tailored website (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard clinical recruitment website (n=50)
Number of subjects: 100
Study: 32673385

Group type: EXPERIMENTAL
Intervention: Lenalidomide/rituximab (R2)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Rituximab/chemotherapy (R-Chemo)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Both R2 and R-Chemo
Number of subjects: 222
Study: 32673446

Group type: EXPERIMENTAL
Intervention: Fedratinib 500 mg daily for 14 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo on day 1
Number of subjects: 60
Study: 32673501

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study: 32673661

Group type: EXPERIMENTAL
Intervention: Ascyrus Medical Dissection Stent (AMDS) implantation
Number of subjects: 47
Study: 32673741

Group type: EXPERIMENTAL
Intervention: Pre-ACLF patients (n=218)
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Unstable decompensated cirrhosis (UDC) patients (n=233)
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Stable decompensated cirrhosis (SDC) patients (n=620)
Number of subjects: 1071
Study: 32674209

Group type: EXPERIMENTAL
Intervention: Nivolumab (Opdivo) plus ipilimumab (Yervoy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 32674336

Group type: EXPERIMENTAL
Intervention: Convection Enhanced Delivery (CED)
Number of subjects: 0
Study: 32674461

Group type: EXPERIMENTAL
Intervention: Sorafenib + Pravastatin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 31
Study: 32674634

Group type: EXPERIMENTAL
Intervention: Evolocumab, 480 mg every 4 weeks for 6 weeks
Number of subjects: 30
Study: 32675047

Group type: EXPERIMENTAL
Intervention: Bone Scintigraphy (BS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Advanced imaging modalities
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional imaging modalities
Number of subjects: 80
Study: 32675217

Group type: EXPERIMENTAL
Intervention: Pulmonary Hypertension (PH)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Right Ventricular Dysfunction (RVD)
Number of subjects: 200
Study: 32675274

Group type: EXPERIMENTAL
Intervention: Practices without central QI support
Number of subjects: 205

Group type: COMPARATOR
Intervention: Practices with central QI support
Number of subjects: 205
Study: 32675292

Group type: COMPARATOR
Intervention: Evening chronotypes (reference group)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Chronotype preference (morning, intermediate, evening)
Number of subjects: 635
Study: 32676125

Group type: EXPERIMENTAL
Intervention: HPV testing on provider-collected specimens
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: HPV testing on self-collected specimens
Number of subjects: 566

Group type: COMPARATOR
Intervention: Visual Inspection after Acetic Acid (VIA)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Overall high-grade cervical abnormality detection
Number of subjects: 566
Study: 32676205

Group type: EXPERIMENTAL
Intervention: iStent implantation in patients with baseline IOP < 26 mmHg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: iStent implantation in patients with baseline IOP ≥ 26 mmHg
Number of subjects: 72
Study: 32411946

Group type: EXPERIMENTAL
Intervention: PrEP demand creation video
Number of subjects: 320
Study: 32676681

Group type: EXPERIMENTAL
Intervention: Emergency medical service (EMS) transported patients
Number of subjects: 15800

Group type: EXPERIMENTAL
Intervention: Pre-existing logistic structure in regional STEMI networks
Number of subjects: 15800

Group type: COMPARATOR
Intervention: Total number of STEMI patients treated
Number of subjects: 15800
Study: 32676697

Group type: EXPERIMENTAL
Intervention: Ophthalmologist's medical report
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Computer-generated documents
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Handwritten documents
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Standard form of national guidelines
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Self-designed formats
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Detailed letters
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Short reports
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Short messages
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Report rate
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Age of reports
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Prevalence of DR in forms
Number of subjects: 810
Study: 32676702

Group type: EXPERIMENTAL
Intervention: Diabetic low-lipid tasters
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Diabetic high-lipid tasters
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Patients treated with metformin and/or statins
Number of subjects: 2
Study: 32676727

Group type: EXPERIMENTAL
Intervention: Magnetic sphincter augmentation (MSA)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Laparoscopic fundoplication (LF)
Number of subjects: 631
Study: 32676980

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) measured by WHOQOL-BREF
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Self-reported impairments measured by SIPP-RS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Activities of daily living measured by IBM-FRS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 6-minute walking distance (6MWD)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Motor function measure (MFM)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Activities of daily living
Number of subjects: 27
Study: 32677025

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive PCR test
Number of subjects: 17787

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive serological test
Number of subjects: 17787

Group type: EXPERIMENTAL
Intervention: Population estimate of SARS-CoV-2 infection
Number of subjects: 17787

Group type: EXPERIMENTAL
Intervention: Population estimate of seropositivity
Number of subjects: 17787

Group type: EXPERIMENTAL
Intervention: Active infection rate
Number of subjects: 17787

Group type: EXPERIMENTAL
Intervention: Prevalence of prior SARS-CoV-2 exposure
Number of subjects: 17787

Group type: EXPERIMENTAL
Intervention: Self-reported symptoms (loss of smell or taste, body aches)
Number of subjects: 17787
Study: 32677106

Group type: EXPERIMENTAL
Intervention: (+)-Epicatechin (EPI) at 75 mg/d for 24 weeks, escalating to 150 mg/d at 12 weeks if no improvement
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: (+)-Epicatechin (EPI)
Number of subjects: 10
Study: 32677243

Group type: EXPERIMENTAL
Intervention: MBSR plus usual care (8 sessions of 2 hr/week)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 85
Study: 32677467

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32677894

Group type: EXPERIMENTAL
Intervention: Intervention involving personalized care practices developed using the Balance of Care methodology, including training for healthcare professionals.
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 430
Study: 32677968

Group type: EXPERIMENTAL
Intervention: Hepatitis-B vaccine with five different adjuvant formulations
Number of subjects: 0
Study: 32677985

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (without levosimendan)
Number of subjects: 200